OCGN
What one share of Ocugen holds
Biological Products, (No Diagnostic Substances)
Ocugen is aiming to redefine the future of vision through game-changing gene therapies with the potential to address significant, unmet medical needs. Our First-in-class, breakthrough modifier gene therapy platform presents a potential paradigm shift in treating inherited retinal diseases and blindness diseases affecting millions across the globe.
Ocugen’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.01 |
|---|---|
| Profit | −$0.26 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.19 |
| Cash and investments | $0.30 |
| Debt | $0.01 |
| Book value | −$0.05 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $0.00 | −$2.18 | $0.02 | −$1.81 | — | $0.66 |
| 2017 | $0.00 | −$0.99 | $0.01 | −$1.03 | — | $0.18 |
| 2019 | $0.00 | −$1.46 | $0.00 | −$1.22 | — | — |
| 2020 | $0.00 | −$0.31 | $0.00 | −$0.13 | — | $0.12 |
| 2021 | $0.00 | −$0.30 | $0.00 | −$0.25 | — | $0.46 |
| 2022 | $0.01 | −$0.40 | $0.02 | −$0.30 | — | $0.33 |
| 2023 | $0.02 | −$0.26 | $0.04 | −$0.30 | — | $0.16 |
| 2024 | $0.01 | −$0.20 | $0.01 | −$0.17 | — | $0.10 |
| 2025 | $0.01 | −$0.23 | $0.00 | −$0.19 | — | −$0.04 |